1. Allergan is planning a sales push for double-chin treatment Kybella. The drugmaker said the campaign will be gender neutral in both content and the programming. Celebrity Khloé Kardashian moderated a panel about the drug in March. (Bloomberg)
2. Christi Shaw, the U.S. lead for Novartis, is stepping down for family reasons, according to an internal company announcement. Her role will be split into two positions that will be filled by Fabrice Chouraqui and Tom Kendris. (NJBIZ)
3. Swiss Pharma International is challenging the patents for Biogen’s multiple-sclerosis treatment Tysabri. U.S. sales of Tysabri hit $1.1 billion in 2015. (BioCentury)
4. Sales of PCSK9 inhibitors — a heralded new class of cholesterol-lowering treatments from Sanofi and Regeneron, and Amgen — have been well below estimates. Results from new outcomes trials, evaluating if Praluent or Repatha improve the risk of death from heart attack or stroke, are expected to unlock the drug class’ blockbuster sales potential, according to analysts. (AP)
5. Anticholinergics, such as Johnson and Johnson’s Benadryl and Pfizer’s Dimetapp, were tied to cognitive impairment and dementia, based on a new analysis. Brain scans of people who had been taking the drugs for at last a month showed reduced brain volume and thickness in regions linked to cognitive function. (Reuters)
